PDCD1 and non-small cell lung carcinoma: In particular, the development of monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) and the programmed death-ligand 1 (PD-L1) has demonstrated significant therapeutic efficacy, substantially improving progression-free survival and overall response rates in a subset of NSCLC patients [3].